Bayer Menopause Drug Shows Positive Result in Late-Stage Trials

Bayer AG said a positive outcome from twin late-stage trials on a promising experimental menopause treatment will help it seek regulatory approval.

The German company published more data on the drug, elinzanetant, which lowers the frequency and severity of hot flashes, and said it met all the research goals in two studies that included about 800 post-menopausal women. The results expanded on positive top-line data that Bayer published in January and confirmed that the therapy, administered orally once a day, outperformed a placebo over a 12-week window.